Patent law

CARDIOGENICS HOLDINGS INC. ANNOUNCES LICENSE AGREEMENT AND DIVIDEND DISTRIBUTION

Retrieved on: 
Friday, September 3, 2021
Expense, Intellectual property law, Patent law, Royalty payment, Forward-looking statement, Dividend, Articles

Caledon, Ontario, Sept. 03, 2021 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTC PINK: CGNH) (theCompany)announced todaythat its subsidiary, CardioGenics Inc. (CardioGenics), has entered into a license agreement with Covidgenics Corp., a private company located in Ontario, which grants to Covidgenics an exclusive 10-year global license of the Companys proprietary technology for its QL Care Analyzer and paramagnetic beads.

Key Points: 
  • Caledon, Ontario, Sept. 03, 2021 (GLOBE NEWSWIRE) -- CardioGenics Holdings Inc. (OTC PINK: CGNH) (theCompany)announced todaythat its subsidiary, CardioGenics Inc. (CardioGenics), has entered into a license agreement with Covidgenics Corp., a private company located in Ontario, which grants to Covidgenics an exclusive 10-year global license of the Companys proprietary technology for its QL Care Analyzer and paramagnetic beads.
  • In order to provide the Companys shareholders an opportunity to participate directly in any increased value that may develop from Covidgenics further development efforts, the Company intends to issue to its shareholders, as a dividend, the Covidgenicsshares received by CardioGenics under the license agreement, subject to compliance with all applicable laws.
  • CardioGenics Holdings intends to deliver the Covidgenics shares to its shareholders on a pro rata basis according to their holdings as of a record date of September 13, 2021.
  • The shares distributed to CardioGenics Holdings shareholders will be held, in the shareholder name, at Covidgenics.

Enertopia Answers Your Provisional Patent Questions

Retrieved on: 
Wednesday, August 4, 2021
Physical sciences, Chemistry, Natural sciences, Patent law, United States patent law, Provisional application, Patent, Adsorption, Lithium

The first provisional patent ENERTOPIA SOLAR BOOSTER adsorbs the radiant heat energy from the solar array panels, heats the water running through the jacket, then deposits it into a storage tank to be reheated.

Key Points: 
  • The first provisional patent ENERTOPIA SOLAR BOOSTER adsorbs the radiant heat energy from the solar array panels, heats the water running through the jacket, then deposits it into a storage tank to be reheated.
  • This is done via provisional patent ones glazed adsorber, which heats the claystone solution to the required process heat temperature for extracting the Lithium.
  • One has twelve months from the filing date of a provisional patent to file for patent-pending paperwork.
  • There can be no assurance that patent #6,024,086 will have a positive impact on Enertopia.

Notice from the Office of the Secretary - Ontario Securities Commission

Retrieved on: 
Friday, July 30, 2021
Chicago and North Western Transportation Company, Patent application, Patent law, Rail transportation in the United States, Transportation in the United States, Midwestern United States

TORONTO, July 30, 2021 /CNW/ -The Applicant, Alvin Jones,filed an Amended Application dated July 16, 2021.

Key Points: 

TORONTO, July 30, 2021 /CNW/ -The Applicant, Alvin Jones,filed an Amended Application dated July 16, 2021.
A copy of the Amended Application dated July 16, 2021 is available at www.osc.ca

Appendix 4C Quarterly Activity Report

Retrieved on: 
Friday, July 30, 2021
Expense, Intellectual property law, Patent law, Royalty payment

Total Operating Activities resulted in net cash usage of US$20.7 million in the quarter ended June 30, 2021.

Key Points: 
  • Total Operating Activities resulted in net cash usage of US$20.7 million in the quarter ended June 30, 2021.
  • This included an investment of US$10.8 million associated with remestemcel-L for SR-aGVHD and COVID-19 ARDS.
  • Specifically:
    Revenues from TEMCELL royalties for the quarter ended June 30, 2021 were US$1.9 million compared to US$0.7 million in the quarter ended June 30, 2020.
  • The DSMB recommended that the trial complete with the enrolled 222 patients, and that all be followed-up as planned.

FADEL Chooses Montréal for its New Research & Development Centre

Retrieved on: 
Thursday, July 29, 2021
Intellectual property law, Patent law, Expense, Royalty payment

NEW YORK, July 29, 2021 /PRNewswire-PRWeb/ --FADEL, an innovative provider of rights & royalty management software, is continuing its growth with a new research and development centre in Montral, marking its expansion in Canada.

Key Points: 
  • NEW YORK, July 29, 2021 /PRNewswire-PRWeb/ --FADEL, an innovative provider of rights & royalty management software, is continuing its growth with a new research and development centre in Montral, marking its expansion in Canada.
  • FADEL has been assisting global brands with IP and content licensing rights, legal compliance, royalty fee calculation and billing management.
  • As a research and development centre, the office will contribute to the creation of new and innovative products filling roles across software development and quality assurance.
  • "The opening of FADEL's research and development centre in Montral is an indisputable example of the vitality of our innovation ecosystem, says Hubert Bolduc, President of Investissement Qubec International.

Spartan Delta Corp. Announces Strategic Montney Acquisition, $150 Million Equity Financing, $450 Million Credit Facility and $150 Million Term Facility

Retrieved on: 
Wednesday, July 28, 2021
Expense, Intellectual property law, Patent law, Royalty payment

CALGARY, Alberta, July 28, 2021 (GLOBE NEWSWIRE) -- Spartan Delta Corp. ("Spartan" or the "Company") (TSXV:SDE) is pleased to announce that it has entered into a definitive agreement (the "Agreement") to acquire Velvet Energy Ltd. ("Velvet"), a privately held light-oil Montney producer with operations primarily in the Gold Creek, Karr and Pouce Coupe areas of north-west Alberta (the "Velvet Assets") for total consideration of approximately $743.3 million(1) (the "Acquisition").

Key Points: 
  • The Net Debt(8) of Velvet being assumed or paid out by Spartan upon closing of the Acquisition is estimated to be $371.7 million, inclusive of Velvet's transaction costs.
  • Total land holdings to be acquired is 384,700 net acres, of which approximately 281,700 net acres represent lands in the Montney formation.
  • Based on working interest reserves of the Velvet Assets before deduction of royalties and without including any of royalty interest reserves.
  • "Net Debt (Surplus)" includes the Term Facility and indebtedness under the Credit Facility, net of Adjusted Working Capital.

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

Retrieved on: 
Tuesday, July 27, 2021
Monopoly, Patent law, Patent portfolio, Patent, Silo, Mario Rodríguez Cobos, Retailers

Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notice of allowance for a patent application related to the Company's Central Nervous System Homing Peptide. 

Key Points: 
  • Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notice of allowance for a patent application related to the Company's Central Nervous System Homing Peptide.
  • "We are pleased to have been granted this patent by the United States Patent and Trademark Office for our novel homing peptide," said Eric Weisblum, CEO of Silo Pharma.
  • "We will continue to expand our intellectual property portfolio related to markets where our novel therapeutics can be applied.
  • Silo Pharma.

Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations

Retrieved on: 
Tuesday, July 27, 2021
Biotechnology, Medical devices, Health, Science, Other Science, Biotechnology companies, 10x Genomics, Patent law, 10x, Companies, Bio-Rad Laboratories, Royalty payment, Royal Academy of Dance

The settlement includes a global patent cross-license for patents held by both Bio-Rad and 10x Genomics, resolving outstanding issues in the field of single-cell genomics.

Key Points: 
  • The settlement includes a global patent cross-license for patents held by both Bio-Rad and 10x Genomics, resolving outstanding issues in the field of single-cell genomics.
  • Under the terms of the settlement, Bio-Rad and 10x Genomics have granted each other a non-exclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis.
  • "We are pleased to put an end to the worldwide litigations in the license agreement between Bio-Rad and 10x Genomics, said Norman Schwartz, Bio-Rad President and Chief Executive Officer.
  • This settlement and the resulting license agreements along with our other recent IP settlement serve as a validation of the importance and value of Bio-Rad's intellectual property rights," he added.

Soundbite Medical Solutions Announces Issuance of a Fourth U.S. Patent Further Expanding Coverage of its Core Technology

Retrieved on: 
Tuesday, July 27, 2021
Health, Medical devices, Cardiology, Monopoly, Patent law, Patent, United States patent law

It protects the novel Soundbite system architecture, which is used in all products of the company's burgeoning portfolio.

Key Points: 
  • It protects the novel Soundbite system architecture, which is used in all products of the company's burgeoning portfolio.
  • The patent is expected to expire in December 2036 and will continue to provide key intellectual property protection for the Company's technology platform.
  • This is the fourth US patent to be issued around the approved Soundbite technology.
  • Soundbite continues to enhance its patent portfolio with additional patent applications that will broaden and strengthen its patent protection in key markets throughout the world.

International Patent Reviews Releases Study on Sun Pharmaceuticals' LEVULAN® KERASTICK® patent

Retrieved on: 
Monday, July 26, 2021
Patent law, Pharmaceuticals policy, Monopoly, Patent, Pharmaceutical industry in China, United States patent law, Chemical patent, Articles, Outline of patents

DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.

Key Points: 
  • DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.
  • However, many pharmaceutical filings are purposefully structured to artificially extend the reach of protection afforded by our patent system."
  • IPR has developed a comprehensive and multifaceted process for identifying pharmaceutical patent filings that have taken advantage of the patent system.
  • The first patent for LEVULAN KERASTICK was issued in January of 1992.